Virbac Q1 Revenue Rises 7.7%, Maintains 2024 Guidance

Virbac Reports Strong Q1 Growth and Confirms Outlook

French animal health company Virbac SA (EPA:VIRB) announced a first-quarter revenue increase of 7.7% at constant exchange rates and scope. The company has maintained its full-year financial guidance, signaling confidence in its performance trajectory for 2024.

Performance Overview

The growth was primarily driven by strong performance in North America, which saw a 20.7% revenue increase, and in international markets, which grew by 9.1%. Europe posted a more modest growth of 2%. The company stated that increased volume contributed approximately 6% to the growth, with pricing adding around 2%. The recent acquisition of Thyronorm contributed about 1% to overall growth, while foreign exchange created a negative headwind of approximately 5.5%.

Economic Impact and Market Outlook

Virbac reaffirmed its full-year guidance, projecting revenue growth between 5.5% and 7.5% at constant exchange rates. The company also expects an adjusted EBITA margin of around 17% and cash generation of approximately €80 million. This stable outlook suggests resilience in the animal health sector despite geopolitical and foreign exchange uncertainties. The companion animal products segment grew by 9.9%, outpacing the farm animal products segment, which increased by 8.4%.

Summary

Virbac's strong first-quarter performance, led by key international markets, has provided a solid foundation for the year. The company's ability to maintain its annual guidance despite foreign exchange pressures indicates operational strength. Investors will continue to monitor regional performance and the integration of new acquisitions as key factors for future growth.

FAQ

Q: What was Virbac's revenue growth in the first quarter?
A: Virbac's revenue grew by 7.7% at constant exchange rates and scope.

Q: Which region was the main driver of Virbac's Q1 growth?
A: North America was the main driver, with a revenue increase of 20.7% at constant exchange rates.

Q: Did Virbac change its financial guidance for 2024?
A: No, the company maintained its full-year guidance, including a revenue growth forecast of 5.5% to 7.5%.

Source: Investing.com